Search

Displaying results 4331 - 4340 of 10000 in total
  1. Drug

    Pyrroloquinoline Quinone

    go.drugbank.com/drugs/DB03205
    Investigational

    A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]

  2. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp. … In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans.

  3. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].

  4. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  5. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    If approved for use, it will be the first available agent for the treatment of NASH. … the liver have been implicated in its pathogenesis[A32119].

  6. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  7. Drug

    ATG002

    go.drugbank.com/drugs/DB05068
    Investigational

    ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process.

  8. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.

  9. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]

    Products: VECTIBIX® 20 MG/ ML, Vectibix Concentrate for Solution for Infusion 100 mg/vial
  10. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. … It is being developed by Peptech.